ArticleInternational journal of genomics2025
Cathepsin Levels and Atrial Fibrillation Risk: Insights From Bidirectional and Multivariable Mendelian Randomization Analyses.
Article in International journal of genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cathepsin Levels and Atrial Fibrillation Risk: Insights From Bidirectional and Multivariable Mendelian Randomization Analyses.International journal of genomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia, contributing to substantial morbidity, mortality, and healthcare burden. While genome-wide association studies (GWAS) have identified numerous genetic variants linked to AF risk, the causal roles of proteolytic enzymes such as cathepsins remain poorly defined. This study employed bidirectional and multivariable Mendelian randomization (MR) approaches to investigate the causal relationship between genetically determined cathepsin levels and AF risk. Methods: Genetic instruments for nine cathepsins were derived from the INTERVAL study ( Results: Genetically elevated cathepsin O levels were significantly associated with increased AF risk (IVW: Conclusion: This study provides genetic evidence that elevated cathepsin O levels-and conditionally cathepsin B-are causally linked to increased AF risk. These findings highlight the potential role of proteolytic enzymes in AF pathogenesis and suggest novel therapeutic targets. All analyses were conducted in European-ancestry populations; replication in diverse cohorts and mechanistic studies are warranted to validate and extend these insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.